AMMONIUM LAURYL SULFATE

Molecular Excipient

Mwt. LogP HBD HBA PSA RB CSP3
266.0 3.7 1 3 64.0 12 1.0
CAS
2235543
UNII
Q7AO2R1M0B
SYNONYMS
ZINC ID(s)
Availability
Present in 57 ZINC catalogs

Known Active Genes

There has not been any activity reported at 10μM or less for this excipient (per ChEBML)

Clinical Trials

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
Code Date Title Phase Status
NCT02227069 2014-09-01 Skin Safety Study to Evaluate the Irritation Potential in Healthy Volunteers Phase 1 Active, Not Recruiting
NCT02256930 2014-09-01 Skin Safety Study to Evaluate the Sensitizing Potential in Healthy Volunteers Phase 1 Active, Not Recruiting
NCT02198963 2014-07-01 21 Day Cumulative Skin Irritation of RUT058-60 Phase 1 Completed
NCT02160574 2014-06-01 Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA Phase 1 Completed
NCT02169154 2014-06-01 A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel Phase 1 Completed
NCT02168478 2014-06-01 Neo-Synalar Modified 48 Hour Patch Test Phase 4 Completed
NCT02117752 2014-04-01 Dermal Tolerability of Dapsone Gel in Healthy Volunteers Phase 1 Completed
NCT02062073 2014-01-01 Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion Phase 1 Completed
NCT02061813 2014-01-01 Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion Phase 1 Completed
NCT01816529 2013-03-01 Topical Safety Study of Topical Diltiazem Hydrochloride Phase 1 Active, Not Recruiting
NCT01821274 2013-03-01 A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design Phase 1 Active, Not Recruiting
NCT01771822 2013-01-01 Ibuprofen 5% Topical Gel CIPT Phase 1 Completed
NCT01787448 2013-01-01 RIPT of Ibuprofen Topical Gel Phase 1 Completed
NCT01430312 2011-09-01 21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation Phase 1 Completed
NCT00781664 2008-10-01 Cumulative Irritation Test Phase 1 Completed
NCT00680095 2007-01-01 Cumulative Irritation Test Phase 1 Completed
NCT02259868 2005-06-01 Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects Phase 1 Completed

(Browse) Purchasable Analogs in ZINC

Dosages

Route Formulation Per Unit Dose
Topical Aerosol
Topical Emulsion 39.75%

More Information

Usage Over Time

Comments